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Mesalamine-containing products are often a ﬁrst-line treatment for ulcerative colitis. Severe adverse reactions to these products,
including cardiovascular toxicity, are rarely seen in pediatric patients. We present a case of a 16-year-old boy with ulcerative colitis
treated with Asacol, a mesalamine-containing product, who developed sudden onset chest pain after four weeks on therapy. Serial
electrocardiograms showed nonspeciﬁc ST segment changes, an echocardiogram showed mildly decreased left ventricular systolic
function with mild to moderate left ventricular dilation and coronary ectasia, and his troponins were elevated. Following Asacol
discontinuation, his chest pain resolved, troponins were trending towards normal, left ventricular systolic function normalized,
and coronary ectasia improved within 24 hours suggesting an Asacol-associated severe drug reaction. Mesalamine-induced
cardiovascular toxicity, although rare, may represent a life-threatening disorder. Therefore, every patient presenting with acute
chest pain should receive a workup to rule out this rare drug-induced disorder.
1.Introduction
Mesalamine-(5-aminosalicylic acid) containing products are
a well-known treatment for inﬂammatory bowel disease,
often as ﬁrst line. Mesalamine’s mechanism of action is not
completely understood, but seems to reduce colonic inﬂam-
mation topically by inhibiting the cyclooxygenase path-
way and the γ-form of peroxisomal proliferator-activated
receptors (PPAR-γ) signaling pathway. Adverse reactions
to mesalamine are uncommon and include mostly gas-
trointestinal upset and headaches [1]. Rare drug reactions
to mesalamine have been described in the literature and
include pancreatitis, blood dyscrasias, cardiovascular prob-
lems, and interstitial nephritis [2]. Although rare, pericardi-
tis, myocarditis, vasculitis, and left ventricular dysfunction
have been described with mesalamine therapy [3–8]. We
present a case of myocarditis with coronary vasculitis as a
reaction to a mesalamine product, Asacol.
2. Case Presentation
This is a case of a 16-year-old Hispanic male without sig-
niﬁcant past medical history admitted for evaluation follow-
ing 3-month history of abdominal pain and bloody diarrhea.
Outpatient pediatric gastroenterology evaluation was nega-
tive for infectious causes, and due to ongoing symptoms,
he was admitted for further evaluation and treatment.
Colonoscopy performed on admission showed pancolitis
with friable tissue, and biopsies were taken conﬁrming
ulcerative colitis (UC) as the diagnosis. He was started on
methylprednisolone 0.5mg/kg/dose twice a day and Asacol
400mg three times a day (30mg/kg/day). His symptoms
persisted, and on hospital day number four his Asacol dose
was increased to 800mg three times per day (60mg/kg/day).
His abdominal pain and bloody diarrhea started to improve
on the new regimen up until hospital day nine when he
developed worsening of symptoms with an acute episode of
bright red blood per rectum. At that point, Azathioprine
4mg/kg/day was added and the patient was started on
total parenteral nutrition. On hospital day number ten,
he developed a right upper arm superﬁcial thrombo-
sis with superimposed methicillin-sensitive Staphylococcus
thrombophlebitis. Hematology was involved, and he was
started on anticoagulation therapy with low-molecular-
weight heparin (LMWH) and cefazolin. A hypercoagulable2 Case Reports in Pediatrics
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Figure 1: Electrocardiogram on day of chest pain onset: sinus tachycardia with no ST segment changes.
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Figure 2: Coronary artery ectasia. Right coronary artery diameter measuring 6mm (a) and left coronary artery diameter measuring 5mm
(b).
workup, including prothrombin 2021A, factor 5 Leiden
mutation, homocysteine, anticardiolipin antibody, protein
C, protein S, lupus anticoagulant, and Antithrombin III,
was obtained and resulted negative. On hospital day eleven,
he was noted to have intermittent systemic hypertension.
Pediatric nephrology was consulted, and a renal ultrasound
was noted to be normal without renal artery thrombosis
or stenosis. His renal function was within normal limits,
and he was started on nifedipine as needed for systolic
blood pressure greater than 150mmHg. His elevated blood
pressure was thought to be secondary to steroids. Over the
course of the hospitalization, his platelets began to drop and
on hospital day number ﬁfteen he had a large episode of
hematochezia and some epixtasis. At that point, the LMWH
was stopped and he received packed red blood cells and
platelet transfusions. Due to persistent thrombocytopenia
with poor response to platelet transfusion, he underwent
a bone marrow aspirate that showed cellular marrow with
active hematopoiesis. He was diagnosed with idiopathic
thrombocytopenic purpura (ITP) with positive antiplatelets
antibodies and was treated with intravenous immunoglobu-
lin (IVIG), 1 gram/kilogram/day, without major events.
On hospital day number twenty-nine, he developed
acute chest pain described as throbbing pain located in
the middle of his chest without radiation. His physical
exam was unremarkable except for elevated blood pressure
at 152/91mmHg and tachycardia with heart rate of 109.
His electrocardiogram showed sinus tachycardia without ST
segment changes (Figure 1). His troponin-I was elevated and
peaked at 0.67ng/mL, and cardiology was consulted.
A transthoracic echocardiogram revealed mild to mod-
erate dilated left ventricle, mild left ventricular systolic dys-
function with an ejection fraction (EF) of 48%, and bilateral
coronary artery ectasia (Figure 2). His right coronary arteryCase Reports in Pediatrics 3
Table 1: Correlation of symptoms progression and diagnostic data on and oﬀ Asacol.
On Asacol
day 29
Oﬀ Asacol
day 1
Oﬀ Asacol
day 2
Oﬀ Asacol
day 3
Oﬀ Asacol
day 7
Symptoms Chest pain Chest pain None None None
Troponin
0.157ng/mL 0.466ng/L 0.341ng/mL 0.148ng/mL <0.010ng/mL
0.447ng/mL 0.406ng/mL
0.67ng/mL
EKG
Sinus Tachycardia
With no ST segment
Changes (Figure 1)
Normal sinus
rhythm with
nonspeciﬁc ST
changes in inferior
leads (Figure 4)
Normal sinus
rhythm with
nonspeciﬁc ST
changes
Normal sinus
rhythm with sinus
arrhythmia and no
ST segment Changes
Normal sinus
rhythm with sinus
arrhythmia and T
wave inversion in
lead III (Figure 5)
ECHO
Mild-moderate
dilated LV Mildly dilated LV Mildly dilated LV Mildly dilated LV Normal LV
EF at 48% EF at 65% EF at 59% EF at 56% EF at 66%
Dilated coronary
arteries
RCA 6mm (Z ≥ +4)
LCA 5mm
(Z = +2).
Proximal dilation of
coronary arteries
Proximal dilation of
coronary arteries
RCA 6.1mm
Proximal dilation of
coronary arteries
RCA 4.5mm
LCA 5mm
LDA 3.4mm
Proximal dilation of
coronary arteries
RCA 3.8mm
LCA 4.8mm
LDA 3.6mm
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 8 16 24 34 40 60 72 100
Hours after chest pain onset
(Asacol discontinued at 24 hours)
T
r
o
p
o
n
i
n
 
I
 
(
n
g
/
d
L
)
Figure 3: Cardiac enzymes trend on and oﬀ Asacol.
measured 6mm in diameter, and the left main coronary
artery was 5mm in diameter. He was noted to have normal
intracardiac anatomy. He was transferred to the pediatric
intensive care unit for close cardiovascular monitoring. A
decision to discontinue Asacol was made on hospital day
thirty, since it was thought to be the most likely etiology
of his symptoms. After Asacol discontinuation, his chest
pain resolved and his troponins were noted to trend towards
normal (Figure 3).
An electrocardiogram on hospital day one oﬀ Asacol
showed normal sinus rhythm with nonspeciﬁc ST segment
changes in the inferior leads (Figure 4). A repeated echocar-
diogram showed improved left ventricular function with an
EF of 59% and improved coronary artery dilation after two
days oﬀ Asacol. An echocardiogram performed three days
following Asacol discontinuation showed mild dilatation of
the left ventricle with normal systolic function (EF 56%)
and improved coronary artery dilation, although there was
mild persistent proximal dilation. His EKG showed normal
sinus rhythm with nonspeciﬁc ST segments changes. His
troponin-I continued to trend down, and he was discharged
home. He was seen on followup after a week of Asacol
discontinuation, and his electrocardiogram showed normal
sinus rhythm with T wave inversion in lead III (Figure 5).
His echocardiogram showed mildly dilated left ventricle
with an ejection fraction of 66% and mildly improved
proximaldilationofthecoronaryarteries.Hisrightcoronary
artery measured 3.8mm, and his left main coronary artery
measured 4.8mm.
3. Discussion
Cardiac complications in patients with inﬂammatory bowel
disease may represent a rare extraintestinal manifestation
or drug-related side eﬀect [3, 7]. Cardiac manifestations of
ulcerative colitis (UC) are uncommon and include pericardi-
tis, pericardial eﬀusion, and few cases of pericardiac tam-
ponade.UC-associatedpericarditisisadiagnosisofexclusion
aftermetaboliccauses,infection,malignancy,andconnective
tissue disorders have been ruled out [9]. Mesalamine-(5-
aminosalicylic acid) induced cardiovascular toxicity, includ-
ing pericarditis, myocarditis, vasculitis, and left ventricular
dysfunction, is a rare complication that has been described
in the literature [3–8]. Mesalamine’s mechanism of action is
not fully understood and includes inhibition of the cyclooxy-
genase pathway and therefore decreased prostaglandins
synthesis and inhibition of the PPAR-γ signaling pathway
resulting in decreased activity of nuclear factor κBa n da sa
consequence decreased inﬂammation in the colon [3, 10].
The speciﬁc mechanism for mesalamine-induced cardiovas-
cular toxicity is not completely understood but is thought to
beahypersensitivityreactionratherthanacytotoxiceﬀect.A
proposed mechanism is humoral-mediated hypersensitivity
in which antibodies formed against mesalamine cross-react4 Case Reports in Pediatrics
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Figure 4: Electrocardiogram 6 hours oﬀ Asacol: normal sinus rhythm and nonspeciﬁc ST changes.
I
II
III
VI
aVR
aVL
aVF
V1
V2
V3
V4
V5
V6
Figure 5: Electrocardiogram 7 days oﬀ Asacol: normal sinus rhythm and T wave inversion lead III.
with cardiac tissue causing inﬂammation [8]. Most cases
of mesalamine-induced cardiovascular toxicity occur 2–
4 weeks after the initial exposure to the drug, although
presentation may be delayed in the setting of concomitant
steroid administration [8]. Resolution of symptoms has
occurred in all reported cases within one week after drug
discontinuation.
In our case, the patient’s onset and resolution of symp-
toms and signs are similar to those reported in the literature.
Within twenty-four hours after Asacol discontinuation, our
patient had normalized left ventricular function (Table 1),
making mesalamine-induced myocarditis the most likely
diagnosis. Coronary artery ectasia, seen in our patient, has
been previously described in a similar case in the literature
and may represent a vasculitis type inﬂammation induced
by mesalamine by a mechanism similar to the one described
above. Although improved after Asacol discontinuation,
mild proximal coronary ectasia persisted one week following
Asacol discontinuation. We will continue to follow this
ﬁnding for further correlation.
Our patient also received IVIG during his hospital stay
forITP,andthereareseveralcasesofnon-STelevationaswell
as ST elevation myocardial infarction described in the adult
literatureinpatientswithpriorriskfactorsforcardiovascular
disease (i.e., hypertension, diabetes, and coronary artery
disease) after a ﬁrst cycle of IVIG; this is likely secondary toCase Reports in Pediatrics 5
hyperviscosity and complement activation causing occlusion
of vessels already narrowed by atherosclerosis [11–13]. Our
patient did not have any risk factor for cardiovascular disease
and his chest pain presented a week after the IVIG infusion.
There are also no reported cases in the pediatric population
making IVIG a very unlikely suspect.
Mesalamine-induced cardiovascular toxicity, although
rare, may represent a life-threatening disorder that requires
immediate discontinuation of the mesalamine-containing
product and adequate supportive treatment. It is suggested
that every patient, on mesalamine, presenting with acute
chest pain, shortness of breath, or any additional cardio-
vascular concern undergoes an electrocardiogram, cardiac
enzymes, and an echocardiogram to rule out this rare drug-
induced disorder.
References
[ 1 ] M .L .S c r i b a n o ,“ A d v e r s e se ﬀects of IBD therapies,” Inﬂamma-
tory Bowel Diseases, vol. 14, no. S2, pp. 210–211, 2008.
[ 2 ]E .V .L o f t u sJ r . ,S .V .K a n e ,a n dD .B j o r k m a n ,“ S y s t e m a t i c
review: short-term adverse eﬀects of 5-aminosalicylic acid
agents in the treatment of ulcerative colitis,” Alimentary
Pharmacology and Therapeutics, vol. 19, no. 2, pp. 179–189,
2004.
[3] O. Atay, K. Radhakrishnan, J. Arruda, and R. Wyllie, “Severe
chest pain in a pediatric ulcerative colitis patient after 5-
aminosalicylic acid therapy,” World Journal of Gastroenterol-
ogy, vol. 14, no. 27, pp. 4400–4402, 2008.
[4] L. Garcia-Ferrer, J. Estornell, and V. Palanca, “Myocarditis
by mesalazine with cardiac magnetic resonance imaging,”
European Heart Journal, vol. 30, no. 8, p. 1015, 2009.
[5] N. Ishikawa, T. Imamura, K. Nakajima et al., “Acute pericardi-
tis associated with 5-aminosalicylic acid (5-ASA) treatment
for severe active ulcerative colitis,” Internal Medicine, vol. 40,
no. 9, pp. 901–904, 2001.
[6] L. Doganay, B. Akinci, N. Pekel, I. Simsek, and H. Akpinar,
“Mesalazine-induced myopericarditis in a patient with ulcera-
tive colitis,” International Journal of Colorectal Disease, vol. 21,
no. 2, pp. 199–200, 2006.
[7] O. Merceron, C. Bailly, and A. Khalil, “Mesalamine induced
Myocarditis,” Cardiology Research and Practice, vol. 2010,
Article ID 930190, 3 pages, 2010.
[8] R. A. Waite and J. M. Malinowski, “Possible mesalamine-
induced pericarditis: case report and literature review,” Phar-
macotherapy, vol. 22, no. 3, pp. 391–394, 2002.
[9] A. Rezaie, K. Wong, and G. Gyenes, “Pericardial Tamponade
in a patient with inactive Ulcerative Colitis,” Case Reports in
Medicine, vol. 2010, Article ID 3524173, 3 pages, 2010.
[10] H. Kim, H. Jeon, H. Kong et al., “A molecular mechanism
for the anti-inﬂammatory eﬀect of taurine-conjugated 5-
aminosalicylic acid in inﬂamed colon,” Molecular Pharmacol-
ogy, vol. 69, no. 4, pp. 1405–1412, 2006.
[11] M. Mizrahi, T. Adar, E. Orenbuch-Harroch, and Y. Elitzur,
“Non-ST elevation Myocardial infarction after high dose
intravenous immunoglobulin infusion,” Case Reports in
Medicine, vol. 2009, Article ID 861370, 4 pages, 2009.
[12] D. Singh-Grewal, A. Kemp, and M. Wong, “A prospective
study of the immediate and delayed adverse events following
intravenous immunoglobulin infusions,”Archives of Disease in
Childhood, vol. 91, no. 8, pp. 651–654, 2006.
[13] S. B. Stenton, D. Dalen, and K. Wilbur, “Myocardial infarction
associated with intravenous immune globulin,” Annals of
Pharmacotherapy, vol. 39, no. 12, pp. 2114–2118, 2005.